### Significant events in influenza vaccination practice in Australia

<table>
<thead>
<tr>
<th>Year</th>
<th>Month</th>
<th>Intervention</th>
</tr>
</thead>
</table>
| Pre-1991 | | Seasonal influenza vaccination recommended for individuals at risk of complications or death from influenza:  
- persons >65 years of age  
- persons of all ages with chronic debilitating disease (2 doses required for children)  
- persons receiving immunosuppressive therapy as well as persons engaged in medical and health services |
| 1991 | | List of at-risk individuals for whom seasonal influenza vaccination recommended expanded to include residents of nursing homes and other chronic care facilities |
| 1994 | | Seasonal influenza vaccination recommended for individuals aged ≥65 years and Aboriginal and Torres Strait Islander people aged ≥50 years  
Seasonal influenza vaccination recommended to be considered for individuals with underlying medical conditions that increased their risk of severe influenza or complications, for residents of nursing homes and other chronic care facilities, and for staff who care for immunocompromised patients and staff of nursing home and other chronic care facilities |
| 1997 | | VIC only: influenza vaccine funded for all adults aged ≥65 years |
| 1999 | | Funding provided for both the national Older Australian Flu Program (for adults aged ≥65 years) and the National Indigenous Pneumococcal and Influenza Immunisation (NIPII) Program (for Aboriginal and Torres Strait Islander people aged ≥50 years and Aboriginal and Torres Strait Islander people aged 15–49 years who had at least one of a range of underlying medical conditions that increased their risk of influenza or complications) |
| 2000 | March | List of underlying medical conditions and population groups for which seasonal influenza vaccination recommended was expanded – additional groups included pregnant women, healthcare workers and travellers under specified conditions  
The recommended upper age for children requiring 2 doses in the first year they receive influenza vaccine specified as <10 years |
| 2003 | September | List of underlying medical conditions and population groups for which seasonal influenza vaccination recommended was further expanded |
| 2008 | January | Seasonal influenza vaccine recommended annually for all Aboriginal and Torres Strait Islander people aged ≥15 years  
WA only: seasonal influenza vaccination program funded for all children aged 6 months to <5 years |
| | April |  |
| 2009 | March | Intradermal influenza vaccine (9 μg) registered for adults aged 18–59 years  
Intradermal influenza vaccine (15 μg) registered for adults aged ≥60 years |
<p>| | March |  |
| | September | Pandemic (A/H1N1 2009) influenza vaccine registered, recommended and funded for children aged ≥10 years and adults (1 dose) |
| | December | Pandemic (A/H1N1 2009) influenza vaccine registered, recommended and funded for children aged 6 months to ≤9 years (2 doses) |</p>
<table>
<thead>
<tr>
<th>Year</th>
<th>Month</th>
<th>Intervention</th>
</tr>
</thead>
</table>
| 2010 | January | Seasonal influenza vaccine funded for:  
| | | - all persons aged ≥6 months with medical conditions predisposing to severe influenza for whom influenza vaccination is recommended (previously subsidised under PBS)  
| | | - pregnant women (previously subsidised under PBS)  
| | | - all Aboriginal and Torres Strait Islander people aged ≥15 years  
| | April | Use of the 2010 seasonal influenza vaccine in children aged <5 years (including the WA vaccination program) suspended due to an increased incidence of high fevers and febrile convulsions post vaccination  
| | August | Use of seasonal influenza vaccine in children aged <5 years resumed. Vaccine associated with increased risk of febrile convulsions (Fluvax, CSL Biotherapies) no longer for use in children aged 6 months to <5 years.  
| | December | Pandemic (A/H1N1 2009) influenza vaccine no longer available  
| 2011 | March | ATAGI/TGA issue revised recommendations for brands of seasonal influenza vaccine for use in children aged 6 months to ≤9 years (due to safety data)  
| | July | First prepandemic (A/H5N1) influenza vaccine registered  
| 2012 | February | Annual ATAGI/TGA recommendations regarding brands of seasonal influenza vaccine for use in children aged 6 months to ≤9 years issued  
| | February | Annual ATAGI/TGA recommendations regarding brands of seasonal influenza vaccine for use in persons aged ≥6 months issued  
| | March | Seasonal influenza vaccine recommended for children aged 6 months–5 years (2 doses)  
| | March | List of underlying medical conditions for which seasonal influenza vaccination recommended expanded to include: Down syndrome without congenital heart disease, obesity (BMI ≥30 kg/m²), alcoholism (not funded under the NIP)  
| | March | List of population groups for which seasonal influenza vaccination recommended further expanded to include homeless people, persons involved in the commercial poultry or pork industry, or in culling poultry or pigs during confirmed avian or swine influenza activity, and persons providing essential services  
| 2013 | August | First inactivated quadrivalent influenza vaccine registered for use in individuals aged ≥3 years  
| 2014 | March | Annual ATAGI/TGA recommendations regarding brands of seasonal influenza vaccine for use in persons aged ≥6 months issued  
| | December | Second inactivated quadrivalent influenza vaccine registered for use in individuals aged ≥6 months  
| 2015 | March | Annual ATAGI/TGA recommendations regarding brands of seasonal influenza vaccine for use in persons aged ≥6 months issued  
| | March | Seasonal influenza vaccine funded for Aboriginal and Torres Strait Islander children aged 6 months to <5 years  
| | March | List of underlying medical conditions for which seasonal influenza vaccination recommended modified to include chronic liver disease (rather than alcoholism) and obesity with BMI ≥40 kg/m²  
| | March | The recommended upper age for children requiring 2 doses in the first year they receive influenza vaccine changed from <10 years to <9 years  
| | March | First cell-based inactivated trivalent influenza vaccine registered for use in adults aged >18 years  
| | June | List of population groups for which seasonal influenza vaccination recommended further expanded to include Aboriginal and Torres Strait Islander children aged 5–14 years  

© NCIRS 2016  
Last updated November 2016
<table>
<thead>
<tr>
<th>Year</th>
<th>Month</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>July</td>
<td>Third inactivated quadrivalent influenza vaccine registered for use in individuals aged ≥18 years</td>
</tr>
<tr>
<td></td>
<td>October</td>
<td>First live attenuated quadrivalent influenza vaccine registered for use in individuals aged 2–&lt;18 years</td>
</tr>
</tbody>
</table>